title: The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.
abstract: This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P = 0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P = 0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P = 0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P < 0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.
authors.affiliation: Department of Cardiothoracic Surgery, Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B Bronx, New York, NY 10467, USA. skeller@montefiore.org
authors.forename: S M
authors.initials: SM
authors.lastname: Keller
authors.forename: M G
authors.initials: MG
authors.lastname: Vangel
authors.forename: S
authors.initials: S
authors.lastname: Adak
authors.forename: H
authors.initials: H
authors.lastname: Wagner
authors.forename: J H
authors.initials: JH
authors.lastname: Schiller
authors.forename: A
authors.initials: A
authors.lastname: Herskovic
authors.forename: R
authors.initials: R
authors.lastname: Komaki
authors.forename: M C
authors.initials: MC
authors.lastname: Perry
authors.forename: R S
authors.initials: RS
authors.lastname: Marks
authors.forename: R B
authors.initials: RB
authors.lastname: Livingston
authors.forename: D H
authors.initials: DH
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012737:Sex Factors; D013534:Survival
chemical_list: D005047:Etoposide; D002945:Cisplatin